Which analgesic medications are appropriate for effective pain control, starting with non‑opioid agents and adding opioids if needed?

Effective Pain Medications: A Stepwise Approach

Start with acetaminophen (up to 4 g/day) and/or NSAIDs (e.g., ibuprofen 400 mg every 4–6 hours) for mild pain; add immediate-release opioids (e.g., oral morphine 20–40 mg every 4 hours with hourly rescue doses) for moderate-to-severe pain, prescribing them on a regular schedule rather than "as needed." 1

First-Line Non-Opioid Analgesics

For mild pain (intensity 1–3 on a 0–10 scale), non-opioid agents are the foundation of treatment:

• Acetaminophen is effective for all pain intensities in the short term and should be dosed at approximately 1,000 mg every 4–6 hours, not exceeding 4 g daily to avoid hepatotoxicity. 1, 2
• NSAIDs (e.g., ibuprofen 400 mg every 4–6 hours or diclofenac gel applied three times daily) provide effective analgesia, particularly for inflammatory or musculoskeletal pain. 1, 2
• Use caution with NSAIDs in patients with gastrointestinal bleeding history, cardiovascular disease, or chronic kidney disease; selective COX-2 inhibitors may reduce GI risk but are more expensive. 2, 3

Adding Opioids for Moderate-to-Severe Pain

When non-opioids alone are insufficient for moderate pain (intensity 4–7) or severe pain (intensity 8–10), opioid therapy becomes necessary:

Opioid-Naïve Patients

• Initiate oral morphine 20–40 mg every 4 hours as the first-line strong opioid, with rescue doses of 10–20% of the total daily dose available hourly for breakthrough pain. 1, 4
• For urgent relief or when oral administration is not feasible, use parenteral morphine 5–10 mg IV or SC, recognizing that the oral-to-parenteral conversion ratio is approximately 1:2 to 1:3. 1, 4
• Titrate using immediate-release formulations with reassessment every 60 minutes for oral dosing and every 15 minutes for IV administration; increase the daily dose by 30–50% until pain relief is achieved. 1, 4

Opioid-Tolerant Patients

• Continue baseline opioid therapy and add short-acting opioids for breakthrough pain, titrating upward by 30–50% of the daily dose as needed. 1
• Opioid-tolerant patients (defined as those taking ≥60 mg oral morphine daily, ≥25 mcg transdermal fentanyl hourly, ≥30 mg oral oxycodone daily, or equianalgesic doses for ≥1 week) typically require higher doses to achieve adequate analgesia. 1

Alternative Strong Opioids

• Oxycodone (1.5–2× more potent than oral morphine) and hydromorphone (7.5× more potent than oral morphine) are acceptable alternatives if morphine is unavailable or poorly tolerated. 1, 4
• Avoid tramadol and codeine as first-line agents due to dose-titration limitations, prodrug metabolism requirements (CYP2D6), and lower analgesic potency compared to strong opioids. 1
• Methadone should only be prescribed by experienced clinicians due to unique pharmacokinetic properties and risk of accumulation. 1

Critical Dosing Principles

Prescribe opioids on a regular, around-the-clock schedule for baseline pain control—never "as needed"—and provide separate rescue doses for breakthrough episodes:

• Once a stable 24-hour opioid requirement is established through immediate-release titration, convert to an extended-release formulation for maintenance therapy. 1, 4
• The oral route is preferred even for severe pain because it provides stable plasma concentrations and ease of dose adjustment. 1, 4
• Reserve parenteral routes (IV/SC) for patients requiring urgent relief, unable to swallow, or with poor oral tolerance. 1, 4

Adjuvant Analgesics for Neuropathic Pain

When pain has a neuropathic component or is only partially responsive to opioids, add coanalgesic agents:

Antidepressants

• Tricyclic antidepressants (e.g., nortriptyline or desipramine 10–25 mg nightly, titrated to 50–150 mg) are first-line for neuropathic pain; secondary amines are better tolerated than tertiary amines (amitriptyline, imipramine). 1
• Duloxetine 30–60 mg daily, increased to 60–120 mg daily, or venlafaxine 50–75 mg daily, increased to 75–225 mg daily, are alternative options. 1

Anticonvulsants

• Gabapentin starting at 100–300 mg nightly, titrated to 900–3,600 mg daily in divided doses (increase by 50–100% every few days), is effective for neuropathic pain; use slower titration in elderly or medically frail patients and adjust for renal insufficiency. 1
• Pregabalin 50 mg three times daily, increased to 100 mg three times daily (maximum 600 mg/day), is more efficiently absorbed than gabapentin and also requires dose adjustment in renal impairment. 1

Topical Agents

• Lidocaine 5% patch applied daily to the painful site provides local analgesia with minimal systemic absorption. 1
• Diclofenac gel applied three times daily or diclofenac patch (180 mg once or twice daily) can be used as coanalgesics. 1

Multimodal Analgesia Strategy

Combine non-opioid analgesics with opioids to enhance overall analgesia and permit lower opioid doses:

• Continue acetaminophen and NSAIDs (when not contraindicated) after opioid initiation to provide synergistic pain relief. 1, 4, 5
• Add adjuvant agents to augment opioid analgesia or mitigate opioid-related adverse effects, thereby widening the therapeutic window. 4

Essential Prophylaxis and Adverse Effect Management

Prevent and manage opioid-related side effects proactively:

• Prescribe laxatives routinely for all patients receiving opioids, as constipation is universal and tolerance does not develop. 1, 4
• Provide antiemetics (metoclopramide or antidopaminergic agents) for opioid-induced nausea and vomiting, which typically resolve within days to weeks. 1, 4
• If sedation persists despite opioid rotation, consider adding caffeine 100–200 mg every 4 hours, methylphenidate 5–10 mg 1–3 times daily, or dextroamphetamine 5–10 mg 1–3 times daily (limit dosing to morning and early afternoon to avoid insomnia). 1

Special Populations: Renal Impairment

In patients with severe renal insufficiency (eGFR <30 mL/min/1.73 m²), modify opioid selection to avoid toxic metabolite accumulation:

• Fentanyl and buprenorphine (IV or transdermal) are the safest opioids in chronic kidney disease stages 4–5 because they have minimal active renal metabolites. 1, 4
• Avoid meperidine, codeine, and morphine in renal insufficiency due to accumulation of active metabolites that cause neurotoxicity (confusion, drowsiness, hallucinations). 1, 4
• Use hydrocodone, oxycodone, and hydromorphone with caution and adjust dosage in renal impairment. 1
• Tramadol and tapentadol are not recommended in renal insufficiency (GFR <30 mL/min/1.73 m²). 1

Common Pitfalls to Avoid

Do not delay strong opioid initiation for severe pain by trialing weak opioids first:

• Weak opioids (codeine, tramadol) are limited to maximal daily doses of 360–400 mg and provide only 10–20% of morphine's analgesic potency, rendering them inadequate for severe pain. 4
• The WHO analgesic ladder permits direct commencement of step 3 (strong opioids) when pain intensity warrants it. 4

Do not prescribe opioids "as needed" for chronic baseline pain:

• Continuous, around-the-clock dosing is essential for baseline pain control, with separate rescue doses (10–20% of total daily dose) reserved for breakthrough episodes. 1, 4

Do not use transdermal fentanyl for initial opioid titration:

• Transdermal fentanyl has slow onset and limited dose-adjustability, making it unsuitable until pain is already controlled with other opioids. 4
• Fentanyl patches should not be placed under forced-air warmers. 1

Do not combine two sustained-release opioids:

• Use one extended-release formulation for baseline control and immediate-release formulations for breakthrough pain. 4